2012 clsi m100 s22 pdf

Read our blog post, how using clsis m100 helps the fight against antimicrobial resistance this edition of the. Twentysecond informational supplement abstract the supplemental january 2012 m100s22 vol. Cdc information center centers for disease control and prevention2. Submission requirements for healthcare facilities, healthcare providers and laboratories in washington state october 23, 2012 1.

Ertapenem bp revised in clsi document m100s22 jan 2012. Identify the major changes found in the new clsi documents m02a11, m07a9, and m100s22. The change of ast guidelines from clsi to eucast led to a clinically. Performance standards for antimicrobial susceptibility testing. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. The interpretations of results were taken from those published by the clsi m100 s22, 2012 and eucast 2012. Interpretive criteria used for susceptibility testing of. Clsi, editor 2012, clinical and laboratory standards insitute. Comparison of clinical laboratory standards institute and. P675 contemporary doxycycline and tetracycline susceptibility. Influence of surfactant polysorbate80 on susceptibility.

Change of antibiotic susceptibility testing guidelines from clsi to eucast. The accuracy of the participant tests are listed in table 2 for 14 antimicrobials with. No previous clsi breakpoints existed for ceftolozanetazobactam. Contemporary activity of colistin and polymyxin b against a worldwide collection of. Performance standards for antimicrobial susceptibility. Change of antibiotic susceptibility testing guidelines. To view a list of clsi documents helpful for covid19 testing click here. Develop a communication strategy for informing clinical staff of updates.

Change of antibiotic susceptibility testing guidelines from clsi to. Twenty second informational supplement january 2012. The qc ranges to be used to determine whether qc passes or fails are those defined by cast manufacturers or the clsi. Breakpoints eliminated from clsi document m100 since 2010 reflects m100, 29th ed.

Breakpoints eliminated from clsi document m100 since. Between july 2011 and june 2012 period b, 2688 isolates 1177 e. Pdf comparison of clinical laboratory standards institute. Nov 01, 20 clsi, editor 2012, clinical and laboratory standards insitute. Clsi methods development and standardization working group. In vitro susceptibility testing of fluoroquinolone. Ampicillin, coamoxiclav, cefuroxime and cefaclor minimum inhibitory concentrations mics were determined by etest on haemophilus test medium. No previous clsi breakpoints existed for ceftaroline.

Antimicrobial susceptibility of invasive haemophilus influenzae, 2012 the antimicrobial susceptibility of all 60 viable invasive isolates of h. Mic determination by broth microdilution according to clsi document m100s22 9 showed that a. Identify the major changes found in the new clsi documents m02a11, m07a9, and m100 s22. The data in the interpretive tables in this supplement are valid only if the. Breakpoints eliminated from clsi document m100 since 2010.

Establishing surveillance for carbapenemresistant enterobacteriaceae in minnesota, 2012 volume 35 issue 4 kristin m. Microbiology labs should be aware of the latest version of m100, performance standards for antimicrobial susceptibility testing m100 s22. The interpretations of results were taken from those published by the clsi m100s22, 2012 and eucast 2012. The clinical laboratory standards institute clsi and the european committee on antimicrobial susceptibility testing eucast guidelines are the most popular breakpoint guidelines used in antimicrobial susceptibility testing worldwide. Apr 11, 2016 the clinical laboratory standards institute clsi and the european committee on antimicrobial susceptibility testing eucast guidelines are the most popular breakpoint guidelines used in antimicrobial susceptibility testing worldwide. Carbapenem intermediate or resistant acinetobacter species. Analyses also considered the use of tetracycline hcl susceptibility results to predict. January 2012 m100 s22 clsi breakpoint additionsrevisions since 2010 date of revision m100 version comments antimicrobial agent enterobacteriaceae aztreonam january 2010 m100 s20 cefazolin january 2010 m100 s20 breakpoints. Press release february 2012 2012 clsi guidelines in the biomic v3 microbiology system the 2012 clsi clinical laboratory standards institute m100s22 guidelines are updated in the biomic v3 software. Enterobacteriaceae revised carbapenem breakpoints disk mm agent clsi m100 s19 2009 clsi m100 s20. Changes include new or updated expert rules, updated ast breakpoints, and new or updated qc breakpoints.

In 2012, clsi published an updated edition of gp17aclinical laboratory safety. Enterobacteriaceae revised carbapenem breakpoints disk mm agent clsi m100s19 2009 clsi m100s20 2010 susc int res susc int res doripenem 23 2022 19 ertapenem 19 1618 15 22 1921 18. Approved standard ninth edition performance standards for antimicrobial susceptibility testing. Microbiology labs should be aware of the latest version of m100, performance standards for antimicrobial susceptibility testing m100s22. In the 2012 m100 s22 document, the clinical laboratory and standards institute clsi revised ciprofloxacin breakpoints for invasive salmonella serotypes, lowering the resistance breakpoint from 4. Reporting and specimen submission requirements for. Typhi and extraintestinal salmonella isolates, the clsi in 2012 indicated that clinicians may consider maximal oral or parenteral cip dosage regimens for those salmonella isolates with cip mics or dd zone diameters in the intermediate range. Clinical and laboratory standards institute january 27 at 11. The clsi voted to remove this comment in m100s23, because isolates that test in the intermediate range. Breakpoint tables for interpretation of mics and zone diameters version 2.

M100s22 replaces m100s21 january 2012 performance standards. Design a strategy for implementing the new practice guidelines into their laboratory practices. January 2012 performance standards for antimicrobial disk susceptibility tests. Performance standards for antimicrobial susceptibility testing clsi. Approved standard eleventh edition methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Clsi creates standards and guidelines for the clinical. Evaluation of oxacillin and cefoxitin disk and mic. Clinical and laboratory standards institute, 940 west valley road, suite 1400, wayne, pennsylvania 19087 usa, 2011. M100 represent the most current information for drug selection, interpretation, and. None of the drugs having clsi breakpoint criteria in m100s22 2012 were observed to be inactive against this p. June 2010, january 2011, january 2012, january 20, january 2014. These standards contain information about disk diffusion m02 and dilution m07 and m11 test procedures for aerobic and anaerobic bacteria. Performance standards for antimicrobial susceptibility testing, 30th edition. Jun 06, 2014 ertapenem bp revised in clsi document m100 s22 jan 2012.

The tables presented in m100 represent the most current information for drug selection. Complete sequence of the blandm1carrying plasmid pndmab. The antimicrobial susceptibility among the 2012 vancomycinresistant e. The 2012 clsi clinical laboratory standards institute m100s22 guidelines are updated in the biomic v3 software. Clinical and laboratory standards institute the clinical and laboratory standards institute clsi is a global, nonprofit, standardsdeveloping organization that promotes the development and use of voluntary consensus standards and guidelines within the healthcare community. Intermediate or resistant to imipenem, doripenem or meropenem and resistant to all tested 3rd generation cephalosporins.

Effects of clinical breakpoint changes in clsi guidelines 20102011 and eucast guidelines 2011 on antibiotic susceptibility test reporting of gram. M100s22 oxacillin disk diffusion performance is inferior to that of cefoxitin for detection of mecamediated oxacillin resistance. New chemistry guidelines have also been published, including expression of measurement uncertainty in laboratory medicine c51a, and assessment of fetal lung maturity by the lamellar body count c58a. The results of these data were presented to the clsi antimicrobial susceptibility testing subcommittee in july 2015, which led to the addition of s. The following antibiotic disks cefar diagnostica ltda were tested. Changes in the tables since the previous edition m100s24 appear in. Reporting and specimen submission requirements for healthcare. In vitro susceptibility testing of fluoroquinolone activity against salmonella. The data in the tables are valid only if the methodologies in clsi documents m02, m07, and m11 are followed. To compare the performance of european committee on antimicrobial susceptibility testing eucast and clsi breakpoints following their revision in 2010, for the detection of extendedspectrum. Clinical and laboratory standards institute, 950 west valley road, suite 2500, wayne, pennsylvania 19087 usa, 2018.